Wednesday · November 18, 2026

 ·  Daily  ·  Newsletters

Resonance network: Quantum InsiderSpace Insider

Business & Markets

Isomorphic Labs Secures $5B to Push AI-Designed Drugs Toward Clinical Trials

Isomorphic Labs, the AI drug-discovery company spun out of Google’s DeepMind in 2021, has secured $5 billion in a Series C round as it prepares to move its AI-designed drug candidates into clinical trials.

Greenoaks and Sequoia Capital co-led the round, joined by new investor Andreessen Horowitz and others. All existing backers also returned, including Alphabet’s GV and CapitalG, Thrive Capital, MGX, Temasek and the U.K. Sovereign AI Fund.

The company has built an AI drug-design engine that draws on a range of simulation models to explore different areas of chemistry. Its work builds on AlphaFold, DeepMind’s protein-structure prediction system, and the company said its programs have produced positive preclinical results in oncology and immunology. It has struck deals with Eli Lilly, Novartis and Johnson & Johnson.

Coming after a $2.1 billion Series B in May, the new capital will fund further development of the engine and expansion into more types of medicine.

The round is the first since founder and CEO Demis Hassabis stepped down as head of DeepMind to focus on drug discovery, moving into a chairman role there. Hassabis and former DeepMind director John Jumper won the Nobel Prize in Chemistry for their work on AlphaFold.

Isomorphic did not disclose its valuation, though Bloomberg reported earlier this month that it was seeking funding at a $50 billion valuation.

James Dargan
About the author
James Dargan

James Dargan is a writer and researcher at The AI Insider. His focus is on the AI startup ecosystem and he writes articles on the space that have a tone accessible to the average reader.

The AI economy, every weekday morning

The daily briefing plus the weekly Scale-ups to watch edition. Free, no spam, unsubscribe any time.